As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer reviewed and may be re-organized for online delivery, but are not copy-edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors.

emmm201303123.reviewer_comments.pdf327KReview Process File

Fig. S1. Heat-map representation of some Mapk genes identified by microarray analysis.

Fig. S2. Creb1 activity increases during oligodendrocyte differentiation.

Fig. S3. Treatment with Pde4 inhibitors promote OPC differentiation in the presence of MAI.

Fig. S4. Quantification of apoptotic cells by TUNEL assay.

Fig. S5. Double immunohistochemistry conducted at the peak of the differentiation phase in remyelinating lesions (14 dpl) confirms expression of activated Erk1/2, p38Mapk and Creb1 in OPCs.

Fig. S6. Rolipram treatment does not change the size of the lesion.

Fig. S7. Experimental scheme and ranking analysis of remyelination.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.